The tables at my web link below include an updated calendar of 80 expected FDA new product decisions and 83 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and the below is a summary of new entries and updates on the calendars.
1.) Genentech (DNA) expects to report results in mid-April in its Avastin colon cancer adjuvant trial, in addition to pending FDA decisions to expand product labels for Avastin in relapsed brain cancer (gliobalstoma) by 5/5/09, Avastin in combination with interferon alfa-2a for the treatment of metastatic renal cell (kidney) carcinoma by 8/1/09, and Xolair (omalizumab) to extend its use in asthma therapy to kids age 6 and older by the end of October.
2.) Takeda Pharma (TKPHY) announced that the FDA would miss the 1/18/09 PDUFA date for its Febuxostat NDA in the treatment of hyperuricemia (once-daily oral treatment of high uric acid levels in gout patients). The FDA is simply behind schedule on pending inspection of clinical trial sites and Febuxostat previously was recommended for approval by an advisory panel.
3.) Dendreon (DNDN) moved up the timeline from mid-year to April for the release of Provenge clinical trial results for prostate cancer as part of its rolling BLA submission.
4.) Genzyme (GENZ) should hear back from the FDA on its sNDA to expand the label for Clolar (clofarabine) in the treatment of adult acute myeloid leukemia - AML). The 1/24/09 date is for the agency to accept the filing and decide if a six-month, priority review will be granted.
5.) ChemGenex Pharma (CXSP) received Orphan Drug status for Omacetaxine in the treatment of Myelodysplastic Syndromes and expected to complete its rolling NDA submission by mid-year.
Hey, I was wondering if you have looked into GNTA, there is a lot of hype surrounding it on chat boards. Let me know what you think, You seem to be into the pahrma's. Thanks. Also, I was looking at DNA, which it looks like you posted as a pick today, I see you are down a tad in the last hour, Is it going to soar soon? Thanks "enjoy the ride"
Sometimes, to find what you want is very difficult, so I will selflessly share my collection of them, http://www.win7productKey.com is a site to sell Windows 7 Product Key, genuine and legitimate Windows 7 Key only 10% of the price of the official To getting people very excited. Tried to buy in, I have confirmed its reliability, I recommend they buy Windows 7 32Bit Product Key.Genuine enjoyment of the right to use, in fact, you only need Windows 7 64Bit Product Key and DL, is that simple and affordable, whether it is Office 2010 Product Key or Office 2007 Product Key, if you remember from the time domain, you will save a large amount of this fee.
ToyWatch is an Italian designer toywatch watch salecompany that specializes in offering luxury style watches at low prices. ToyWatch's American subsidiary, ToyWatch USA, is based in Chicago and is owned by Randy Gordon. white toy watch Fluo Model in BlueToyWatch USA helped popularize the craze for fashion watches with plastic bracelet-style toywatch watchbands. The company has some famous clientele, including First Lady Michelle Obama, Oprah Winfrey, and several young Hollywood actors toywatch watch and celebrities.The watches have been featured on Oprah's 'Favorite Things' list for 2007, and The Ellen toy watchesDeGeneres show.Global:2010 Toy Watch opens in India (Mumbai and Delhi).
Data powered by FinancialContent.
All Rights Reserved.
Quotes delayed at least 20 minutes unless otherwise indicated.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
$82.45 (01/21/09)
